Marcelo V. Negrao

Associate Professor of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center

Appears in 1 story

Last updated Oct 26, 2026

Stories

Lilly's olomorasib shows durable first-line activity in KRAS G12C lung cancer at ESMO

New Capabilities

Presenting author of the olomorasib data at ESMO 2026

KRAS G12C-mutant non-small cell lung cancer has no approved first-line targeted therapy. Standard care is immunotherapy with or without chemotherapy, and most patients never reach second-line treatment, so the first choice carries a lot of weight.

Updated Oct 26